ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Regulation FD Disclosure
Item 7.01.
| Regulation FD Disclosure |
| Item 8.01. | Other Items |
Presentation relating to Abeona Therapeutics Inc. The
presentation is attached as Exhibit 99.1 and is incorporated
herein.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.1 | Presentation entitled Abeona Therapeutics |
| 99.2 |
Press release dated February 17, 2017, entitled Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium 2017 |
About ABEONA THERAPEUTICS INC. (NASDAQ:ABEO)
Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard. ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Recent Trading Information
ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) closed its last trading session down -0.15 at 6.00 with 611,021 shares trading hands.
